Baillargeon 2004

1 Treatments

Studied treatment  metformin 850 mg BID

Control treatment  placebo

Concomittant treatments  

Women (%)  

Age (mean), years  

2 Patients

Patients  Non obese women with PCOS

Inclusion criteria  

Exclusion criteria  

Weight (kg)  

Body-mass index (kg/m2)  

Waist circumference (cm)  

obesity  

Family history of diabetes mellitus (%)  

Definitions of impaired glucose tolerance and type 2 diabetes  

3 Methods

Blinding  

Design  

Centers  

Geographical area  

Sizes  32/32

fasting plasma glucose (mmol/L)  

Downloaded from www.trialresultscenter.org
2-h plasma glucose (mmol/L)

Dyslipidaemia

2hPG (>9.4–11.0 mmol/L)

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>hospitalization for heart failure</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV death, MI, stroke</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>diabetes</td>
<td>-32</td>
<td>-32</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>fatal and non fatal MI</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>normoglycemia</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>fatal and non fatal stroke</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiovasculaire events</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References